Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting
Retrieved on:
Monday, August 29, 2022
Muscle weakness, Lists of diseases, Security (finance), Mitochondrion, Total permanent disability insurance, Safety, INFORM, Hospital, Program, Disorder, Myopathy, Gene, Rhabdomyolysis, Brain, Disease, Death, Severe cognitive impairment, Tissue, Heart, PMM, Exercise intolerance, Deafness, DNA, Prognosis, Encephalopathy, A-DNA, U.S. Securities and Exchange Commission, Myalgia, Natural history, International Network of Health Promoting Hospitals and Health Services, GLOBE, Adenosine triphosphate, Nasdaq, Population, ATP, Adult, Parallel Walk Test, Liver, Hypoglycemia, Private Securities Litigation Reform Act, Lethargy, Metabolism, Sudden death, Mitochondrial trifunctional protein deficiency, Life, Patient, Pharmaceutical industry, Dietary supplement
The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.
Key Points:
- The poster presentations highlight the results of two recently completed clinical trials in patients with long-chain fatty acid oxidation disorders (LC-FAOD), including a successful REN001 Phase 1b study and a non-interventional natural history study.
- Improvements in 12-minute walk test distance and physical functioning scores were observed in a subgroup of patients.
- The poster presentations elaborate on results first announced by the company in July 2022 and highlight the unmet medical need of patients with LC-FAOD.
- REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.